STAAR Surgical Generates $464,000 in Cash from Operations During Thi...(------- Total Sales 100.0% ...),Health

Date:11/2/2009

------- Total Sales 100.0% $55,514 100.0% $56,737 -2.2% ======= ======= Product Sales IOLs 44.8% $24,863 42.9% $24,320 2.2% ICLs 28.8% $15,962 25.9% $14,680 8.7% Other 26.5% $14,689 31.3% $17,737 -17.2% ------- ------- Total 100.0% $55,514 100.0% $56,737 -2.2% ======= ======= STAAR Surgical Company Condensed Consolidated Balance Sheets (in 000's) Unaudited October 2, January 2, 2009 2009 ---- ---- Cash and cash equivalents $5,644 $4,992 Short-term investments - restricted 7,368 179 Accounts receivable trade, net 9,411 8,422 Inventories, net 15,296 16,668 Prepaids, deposits, and other current assets 2,196 2,009 ----- ----- Total current assets 39,915 32,270 ------ ------ Property, plant, and equipment, net 5,180 5,974 Intangible assets, net 5,039 5,611 Goodwill 7,847 7,538 Other assets 1,242 1,189 ----- ----- Total a
'/>"/>

SOURCE STAAR Surgical Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Related medicine technology :

1. STAAR Surgical to Present at the 20th Annual Oppenheimer Healthcare Conference in New York
2. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
3. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
5. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
6. New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems
7. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
8. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
9. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
10. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
11. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery